This article, “SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials”, was published in the October 2017 edition of Diabetologia. It presents the findings of medical researchers who conducted a systematic literature review to identify randomized controlled trials that reported cancer events in Type-2 diabetes patients treated with Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitors for at least 24 weeks.
From the Abstract for this Diabetologia medical journal article:
Results: In total, 580 incidences of cancer among 34,569 individuals were identified from 46 independent RCTs with a mean trial duration of 61 weeks. When compared with comparators (placebo or other active glucose-lowering treatments), SGLT2 inhibitors were not significantly associated with an increased risk of overall cancer (OR 1.14 [95% CI 0.96, 1.36]). For pre-specified cancer types, the risk of bladder cancer might be increased with SGLT2 inhibitors (OR 3.87 [95% CI 1.48, 10.08]), especially [Jardiance (empagliflozin)] (OR 4.49 [95% CI 1.21, 16.73]). Interestingly, [Invokana (canagliflozin)] might be protective against gastrointestinal cancers (OR 0.15 [95% CI 0.04, 0.60). [Emphasis added.]
For years there has been a lingering concern over whether SGLT2 inhibitors are associated with the development of bladder cancer.
This recent medical journal article singles out the SGLT2 inhibitors which contain the active ingredient empagliflozin, which are listed below:
- Jardiance (empagliflozin) — Boehringer Ingelheim Pharmaceuticals — FDA Approval: 2014
- Glyxambi (empagliflozin and linagliptin) — Boehringer Ingelheim Pharmaceuticals — FDA Approval: 2015
- Synjardy (empagliflozin and metformin hydrochloride) — Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company — FDA Approval: 2015
- Synjardy XR (empagliflozin and metformin hydrochloride) — Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company — FDA Approval: 2016
Of course, we will continue to monitor this drug safety issue and report significant developments.[View article at original source]
Strictly Confidential, No Obligation.